A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin

Atherosclerosis

Volumn 154, Issue 3, 2001, Pages 633-640

  Turban, Sharon ^a   Fuentes, Francisco ^a   Ferlic, Laura ^a   Brugada, Ramon ^a   Gotto, Antonio M ^b   Ballantyne, Christie M ^a   Marian, Ali J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coronary artery disease; Genetics; Paraoxonase; Polymorphism

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ARGININE; ARYLDIALKYLPHOSPHATASE; FLUINDOSTATIN; GLUTAMINE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; ARYLDIALKYLPHOSPHATASE; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; ESTERASES; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENOTYPE; HUMANS; INDOLES; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 0035864678     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00495-0     Document Type: Article

References (41)

1. Low density lipoprotein oxidation and its pathobiological significance
2. At last, direct evidence that lipoxygenases play a role in atherogenesis
3. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
4. HDL, its enzymes and its potential to influence lipid peroxidation
5. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
6. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
7. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
8. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein
9. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein
10. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation
11. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation
12. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
13. Human and rabbit paraoxonases: Cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification
14. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon
15. The molecular basis of the human serum paraoxonase activity polymorphism
16. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
17. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation
18. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid oxidation
19. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
20. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
21. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
22. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
23. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
24. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
25. The Gln/Arg polymorphism of human paraoxonase (PON192) is not related to myocardial infarction in the ECTIM study
26. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
27. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
28. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients
29. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan
30. Genetic dissection of complex traits
31. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites
32. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians
33. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
34. The Lipoprotein and Coronary Artherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia
35. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
36. A simple salting-out procedure for extracting DNA from human nucleated cells
37. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity toward paraoxon and is unaffected by the Q→R genetic polymorphism
38. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
39. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
40. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
41. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese